<DOC>
	<DOCNO>NCT01128959</DOCNO>
	<brief_summary>The purpose study assess safety tolerability intravenous ( IV ) carbamazepine ( CBZ ) administer multiple 15 minute infusion single 5 minute infusion adult patient epilepsy stable high dose oral CBZ .</brief_summary>
	<brief_title>Study Assess Safety Tolerability Intravenous Carbamazepine Adults With Epilepsy</brief_title>
	<detailed_description>This phase III , multicenter , open-label study design ass safety tolerability intravenously administer CBZ adult patient epilepsy . This study include 28 day Lead-in Period , Confinement Period ( 7 day 6 night ) 28 day Follow-up Period . Patients begin confinement Day -1 trial , continue take oral CBZ prescribe investigator . On morning Day 0 , Day 4 , Day 17 , patient begin 24hr urine collection evaluation urinary biomarkers . All patient temporarily discontinue prescribed oral CBZ begin IV CBZ administration morning Day 1 , continue administration every 6 hour ( Q6h ) morning Day 4 .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>1 . The patient legal representative must able read , understand , sign date IRB approve Informed Consent Form HIPAA Authorization prior study participation . 2 . The patient man nonpregnant woman least 18 year age . 3 . If woman : Patient either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomay hysterectomy ) , childbearing potential , must comply method birth control acceptable investigator study , least 28 day prior Day 1 28 day follow completion study . Patient breastfeed . Patient childbearing potential must negative serum pregnancy test Day 28 negative urine pregnancy test serum pregnancy test Day 1 . 4 . The patient diagnose approve epilepsy indication CBZ : Partial seizure complex symptomatology ( psychomotor , temporal lobe ) Generalised tonic clonic seizure ( GTCS ) ( grand mal ) : myoclonic , clonic , tonic , tonicclonic , atonic Mixed seizure pattern include , partial generalise seizure ( except absence seizure please see exclusion point number 12 ) 5 . The patient receive stable dose oral CBZ ( tablet capsule formulation ) 1200 mg/day 2000 mg/day , minimum 14 day prior Day 28 . 6 . The patient receive constant dose concomitant medication use chronic condition , ( include OTC medication herbal supplement ) minimum 28 day prior Day 1 . 7 . The patient expect change his/her baseline AED treatment treatment period . 8 . The patient able comply maintain accurate Seizure antiepileptic drug diary . 9 . The patient able comply study procedure include comply protocol determine dose interval , confinement investigative site 6 night 7 day , agree participate entire study . 1 . The patient know hypersensitivity CBZ , Captisol , tricyclic compound , amitriptyline , trimipramine , imipramine ; oxacarbazepine , phenytoin , analogues metabolite . 2 . The patient history previous bone marrow depression . 3 . The patient history intolerance IV administration medication . 4 . The patient pregnant lactating . 5 . The patient treat monoamine oxidase ( MAO ) inhibitor . 6 . The patient use oral , intramuscular , hormone delivery method primary form birth control . 7 . The patient ECG correct QT interval Fridericia 's correction formula ( QTcF ) great 450 msec Screening Day 1 . 8 . The patient screening ALT , AST bilirubin &gt; =3 time upper limit normal . 9 . The patient estimate ClCR ( base CockcroftGault ) &lt; 50 ml/min . 10 . The patient clinically significant illness/infection surgical procedure within 30 day prior Screening . 11 . The patient significant history cardiac , renal , neurologic ( epilepsy ) , psychiatric , oncologic , endocrinologic , metabolic , hepatic disease , would adversely affect participation study . 12 . The patient receive oral CBZ absence seizure . 13 . The patient episode status epilepticus within 4 week Screening . 14 . The patient history severe serious adverse reaction CBZ ( example , aplastic anemia , agranulocytosis , SJS . 15 . The patient take used investigational drug device 30 day prior Screening . 16 . The patient previously administer IV CBZ previous clinical trial ( example OV1015 ) . 17 . The patient urine toxicology screen positive phencyclidine , benzodiazepine ( unless due patient 's concomitant AEDs ) , cannabinoids , cocaine , amphetamine , opiate , barbiturate ( unless due patient 's concomitant AEDs ) , alcohol Screening Day 1 . 18 . The patient diagnosis drug alcohol abuse within past year prior Screening . 19 . The patient significant blood loss ( &gt; 500 mL ) donation within 14 day Screening . 20 . The patient history poor oral CBZ compliance . 21 . The patient participate weight loss nicotine cessation program . 22 . The patient history increase intraocular pressure medication glaucoma . 23 . The patient consider investigator unsuitable candidate study , may include increase frequency , severity duration seizures PreTreatment Period ( Days 280 ) . 24 . The patient previously participate study . 25 . The patient member site personnel immediate family .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Intravenous Carbamazepine</keyword>
	<keyword>Oral Carbamazepine</keyword>
</DOC>